Unión Europea - estonio - EMA (European Medicines Agency)

mylan pharmaceuticals limited - anagrelide vesinikkloriid - trombotsüteemia, olulised - antineoplastilised ained - anagrelide on märgitud, et vähendada kõrgenenud trombotsüütide loeb ohus oluline thrombocythaemia (et) patsientidel, kes ei talu oma praeguse ravi kohta või kelle suurenenud trombotsüütide arv ei ole vastuvõetava tasemeni vähendada oma praeguse ravi. an at-risk patientan at-risk essential thrombocythaemia patient is defined by one or more of the following features:>60 years of age ora platelet count >1,000 x 10⁹/l ora history of thrombo-haemorrhagic events.

Estonia - estonio - Ravimiamet

sandoz pharmaceuticals d.d. - terbinafiin - tablett - 250mg 98tk; 250mg 14tk; 250mg 56tk; 250mg 10tk; 250mg 8tk; 250mg 42tk; 250mg 100tk

Estonia - estonio - Ravimiamet

sandoz pharmaceuticals d.d. - bosentaan - õhukese polümeerikattega tablett - 125mg 56tk; 125mg 14tk

Estonia - estonio - Ravimiamet

sandoz pharmaceuticals d.d. - bosentaan - õhukese polümeerikattega tablett - 62,5mg 112tk; 62,5mg 14tk

Unión Europea - estonio - EMA (European Medicines Agency)

mylan pharmaceuticals limited - acetylsalicylic acid, clopidogrel hydrogen sulfate - acute coronary syndrome; myocardial infarction - antitrombootilised ained - clopidogrel/atsetüülsalitsüülhape mylan on näidustatud sekundaarseks ennetamiseks atherothrombotic sündmuste täiskasvanud patsientidel, arvestades juba nii clopidogrel ja atsetüülsalitsüülhape (asa). clopidogrel/atsetüülsalitsüülhape mylan on fikseeritud annuse kombinatsioon ravimi jätkamine ravi:non-st segmendi elevatsiooniga äge koronaarsündroom (ebastabiilne stenokardia või mitte-q-wave müokardiinfarkt), k.a patsiendid toimumas stent paigutuse pärast perkutaanne südame interventionst segmendi elevatsiooniga ägeda müokardiinfarkti meditsiiniliselt ravitud patsientide abikõlblikud trombolüütiline ravi.

Estonia - estonio - Ravimiamet

sandoz pharmaceuticals d.d. - sorafeniib - õhukese polümeerikattega tablett - 200mg 56tk; 200mg 60tk; 200mg 112tk; 200mg 28tk

Estonia - estonio - Ravimiamet

sandoz pharmaceuticals d.d. - sorafeniib - õhukese polümeerikattega tablett - 400mg 84tk; 400mg 56tk; 400mg 112tk; 400mg 30tk; 400mg 28tk

Unión Europea - estonio - EMA (European Medicines Agency)

pfizer ireland pharmaceuticals - avibactam sodium, ceftazidime pentahydrate - pneumonia, bacterial; soft tissue infections; pneumonia; urinary tract infections; gram-negative bacterial infections - antibacterials süsteemseks kasutamiseks, - zavicefta is indicated in adults and paediatric patients aged 3 months and older for the treatment of the following infections:complicated intra-abdominal infection (ciai)complicated urinary tract infection (cuti), including pyelonephritishospital-acquired pneumonia (hap), including ventilator associated pneumonia (vap)treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above. zavicefta is also indicated for the treatment of infections due to aerobic gram-negative organisms in adults and paediatric patients aged 3 months and older with limited treatment options. tuleks arvesse võtta ametlikke juhiseid sobiva kasutada antibakteriaalseid aineid.

Unión Europea - estonio - EMA (European Medicines Agency)

pfizer ireland pharmaceuticals - ceftaroline fosamil - community-acquired infections; skin diseases, infectious; pneumonia - antibacterials süsteemseks kasutamiseks, - zinforo is indicated for the treatment of the following infections in neonates, infants, children, adolescents and adults: , complicated skin and soft tissue infections (cssti), community-acquired pneumonia (cap) , consideration should be given to official guidance on the appropriate use of antibacterial agents.

Estonia - estonio - Ravimiamet

alembic pharmaceuticals europe limited - olmesartaanmedoksomiil - õhukese polümeerikattega tablett - 10mg 28tk; 10mg 14tk; 10mg 98tk; 10mg 20tk; 10mg 56tk; 10mg 90tk